Quick Answer
Cardiff Oncology, Inc. reported Operating Income Loss of -$48.96 million for the year ending 2025.
- Cardiff Oncology, Inc. showed a decrease of -0.6% in Operating Income Loss from 2024 to 2025.
- This data is from Cardiff Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: -$720.0 thousand | Q2 2011: -$647.5 thousand | Q3 2011: -$732.2 thousand | Q1 2012: -$1.13 million | Q2 2012: -$1.25 million | Q3 2012: -$1.04 million | Q1 2013: -$2.39 million | Q2 2013: -$2.37 million | Q3 2013: -$3.08 million | Q1 2014: -$3.26 million | Q2 2014: -$3.24 million | Q3 2014: -$3.94 million | Q1 2015: -$4.85 million | Q2 2015: -$6.63 million | Q3 2015: -$6.41 million | Q1 2016: -$10.46 million | Q2 2016: -$9.98 million | Q3 2016: -$9.92 million | Q1 2017: -$10.13 million | Q2 2017: -$5.89 million | Q3 2017: -$5.80 million | Q1 2018: -$4.66 million | Q2 2018: -$4.44 million | Q3 2018: -$3.86 million | Q1 2019: -$3.96 million | Q2 2019: -$4.22 million | Q3 2019: -$4.21 million | Q1 2020: -$4.12 million | Q2 2020: -$4.10 million | Q3 2020: -$4.36 million | Q1 2021: -$5.44 million | Q2 2021: -$6.89 million | Q3 2021: -$7.00 million | Q1 2022: -$11.07 million | Q2 2022: -$10.44 million | Q3 2022: -$8.99 million | Q1 2023: -$12.05 million | Q2 2023: -$12.21 million | Q3 2023: -$10.82 million | Q1 2024: -$10.93 million | Q2 2024: -$12.55 million | Q3 2024: -$12.60 million | Q1 2025: -$14.38 million | Q2 2025: -$14.78 million | Q3 2025: -$11.97 million.
- Over the full 15 years of available data (2011 to 2025), Cardiff Oncology, Inc.'s Operating Income Loss has declined by 1,544.7%.
- Historical annual values: Fiscal year 2025: -$48.96 million | Fiscal year 2024: -$48.65 million | Fiscal year 2023: -$45.41 million | Fiscal year 2022: -$39.90 million | Fiscal year 2021: -$28.86 million | Fiscal year 2020: -$19.09 million | Fiscal year 2019: -$16.68 million | Fiscal year 2018: -$17.05 million | Fiscal year 2017: -$25.60 million | Fiscal year 2016: -$40.15 million | Fiscal year 2015: -$25.27 million | Fiscal year 2014: -$14.95 million | Fiscal year 2013: -$10.69 million | Fiscal year 2012: -$4.85 million | Fiscal year 2011: -$2.98 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: